PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27738482-16	2016	CONCLUSIONS: Tofogliflozin may offer a new option for patients whose T2DM remains inadequately controlled on insulin therapy with or without additional oral glucose-lowering agents.	6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol	13-26	insulin	Homo sapiens	109-116